TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6350033
Drug: Acetylcysteine 200
Normalized name: acetylcysteine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 200 mg b.i.d. for 6 months
Study: 24474302
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg days 1 and 15, rifampicin 600 mg days 8-14
Study: 24474302
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg day 1, erlotinib 450 mg day 15, rifampicin 600 mg days 8-18
Study: 24474302
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (erlotinib 150 mg days 1 and 15)
Study: 12356782
Drug: Glucose plus
Normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose plus 0.08 g/kg body weight of Z‐trim
Study: 12356782
Drug: Glucose plus
Normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose plus 0.17 g/kg body weight of Z‐trim
Study: 12356782
Drug: Glucose plus
Normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose plus 0.33 g/kg body weight of Z‐trim
Study: 12356782
Drug: Glucose alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose alone (1 g/kg body weight)
Study: 9683311
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and omeprazole
Study: 25927936
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of parenteral nutrition (PN) beyond PICU-day 7 when enteral nutrition (EN) fails
Study: 25927936
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of parenteral nutrition (PN) within the first days to reach caloric target (control group)
Study: 24432675
Drug: Ruji Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruji Recipe (RR) therapy
Study: 22151676
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen (50:50) self-administered until pain relief achieved (max 15 min)
Study: 22151676
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 µg/kg) as a single dose
Study: 16382319
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 400 IU plus calcium 1 g daily
Study: 10886045
Drug: ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (RCM)
Study: 10886045
Drug: bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth subcitrate 240 mg b.d. + amoxycillin 1000 mg b.d. + metronidazole 500 mg b.d. (BAM)
Study: 10886045
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg o.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (OCM)
Study: 10886045
Drug: Sensitivity to
Normalized name: Colgate Total SF Antisensitivity Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity to both antibiotics
Study: 2950915
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole cream and shampoo
Study: 25555593
Drug: Wufuxinnaoqing Soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wufuxinnaoqing Soft Capsule (WSC)
Study: 23988379
Drug: Intravenous idursulfase
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous idursulfase 0.5 mg/kg weekly for two years
Study: 20227099
Drug: Postoperative enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative enteral infusion of the same enriched formula
Study: 10372954
Drug: High-dose physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose physostigmine infusion (1-1.5 mg over 45-60 min)
Study: 10372954
Drug: Chronic physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic physostigmine administration (2-12 mg/day)
Study: 10372954
Drug: Physostigmine (cognition-enhancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (cognition-enhancing doses)
Study: 2053197
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg 17 beta‐oestradiol
Study: 16125527
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone administration
Study: 25027585
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg daily for 12 weeks)
Study: 25027585
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg daily for 12 weeks)
Study: 20831683
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2
Study: 18619812
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors and atypical antipsychotics
Study: 11220983
Drug: Milk fermented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fermented by Lactobacillus casei (10(8) cfu/ml)
Study: 15757856
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose FSH (375 IU) during the early follicular phase (group A)
Study: 15757856
Drug: 5 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 consecutive low doses FSH (75 IU/day) starting in the mid follicular phase (group B)
Study: 15757856
Drug: Daily low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low doses FSH (75 IU/day) during the early to late follicular phase (groups C, D, E)
Study: 10683601
Drug: Androstenedione supplementation
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione supplementation (200 mg daily for 2 days)
Study: 9587536
Drug: Vaccination group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination group: 3 i.m. injections of GenHevac B followed by one booster at month 9
Study: 9587536
Drug: Serovaccination group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serovaccination group: same vaccination schedule followed by one i.m. injection of anti‐HBs immunoglobulins (500 IU)
Study: 8314383
Drug: Aminoglutethimide (AGT)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AGT) 125 mg twice daily
Study: 8314383
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 20 mg twice daily
Study: 23731911
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (rotigotine or cabergoline)
Study: 10743984
Drug: Critical pathway
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical pathway (levofloxacin treatment)
Study: 1548352
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (10 mg/day)
Study: 27543797
Drug: ABT-719 800
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-719 800 μg/kg
Study: 27543797
Drug: ABT-719 1600
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-719 1600 μg/kg
Study: 27543797
Drug: ABT-719 2100
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-719 2100 μg/kg
Study: 21737704
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g bolus before incision, 400 mg/h infusion during surgery)
Study: 21737704
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution infusion)
Study: 18217908
Drug: Once-daily cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily cyclosporine dosing (group B)
Study: 18217908
Drug: Once-daily cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily cyclosporine dosing with 25% dose reduction (group C)
Study: 18217908
Drug: Twice-daily cyclosporine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily cyclosporine dosing (group A)
Study: 18217908
Drug: Conversion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversion to once-daily dosing
Study: 19880675
Drug: SB-681323 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-681323 7.5 mg
Study: 19880675
Drug: SB-681323 25
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-681323 25 mg
Study: 19880675
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg
Study: 11903939
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline)
Study: 11903939
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) morphine (0.1 mg x kg(‐1) i.v. immediately after intubation, with postoperative bolus doses of 0.5 mg, 1 mg, or 1.5 mg based on weight)
Study: 9783498
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg/d for 12 weeks, increased to 10 mg/d if DBP >= 95 mm Hg after 4 weeks)
Study: 9783498
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg/d)
Study: 3665118
Drug: Pre‐operative bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐operative bromocriptine therapy
Study: 3665118
Drug: Pre‐operative bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐operative bromocriptine therapy for macroprolactinomas
Study: 25947264
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg of oral paracetamol, 60 min before examination
Study: 23995795
Drug: Narrow-band ultraviolet
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band ultraviolet B (NB-UVB) treatment
Study: 12856249
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (Botox; Allergan, Ettlingen, Germany) injections into masticatory muscles
Study: 10566717
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (7.5 mg mixed with apple juice)
Study: 8735681
Drug: TROPDEX (tropisetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: TROPDEX (tropisetron 5 mg i.v. + dexamethasone 20 mg i.v. on day 1, followed by oral tropisetron 5 mg daily and dexamethasone 4 mg twice daily from day 2 to 6)
Study: 8735681
Drug: METDEX (metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: METDEX (metoclopramide 1 mg kg‐1 i.v. + dexamethasone 20 mg i.v. + diphenhydramine 25 mg i.v. on day 1, followed by oral metoclopramide 20 mg 6 hourly from day 2 to 6)
Study: 24655586
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine fumarate extended release (QXR) 300 mg/day
Study: 24655586
Drug: Escitalopram (ESC)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (ESC) 10 mg/day
Study: 14976046
Drug: Prolonged rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged rituximab administration (375 mg/m(2) every 2 months for 4 times)
Study: 14976046
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after initial response or stable disease
Study: 14976046
Drug: Prolonged rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged rituximab administration
Study: 14976046
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment in chemotherapy-naive patients
Study: 14976046
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment in patients responding to induction treatment
Study: 1439632
Drug: Control (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neither treatment)
Study: 3895024
Drug: Methicillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methicillin (200 mg/kg divided into six i.v. doses during 24 hours starting at the induction of anesthesia)
Study: 31776740
Drug: Low-dose CT-guided
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT-guided lung biopsy
Study: 31776740
Drug: Standard-dose CT-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT-guided lung biopsy
Study: 27091236
Drug: OnabotulinumtoxinA 200
Normalized name: onabotulinumtoxinA 200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA 200 or 300 U administered as needed for symptom control
Study: 20100374
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (300 g daily for 6 weeks)
Study: 20100374
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (300 g daily for 6 weeks)
Study: 19074086
Drug: Thrombopoietin receptor
Normalized name: Thrombopoietin receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombopoietin receptor agonists (TPO receptor agonists)
Study: 19074086
Drug: Novel compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel compounds designed to stimulate the TPO receptor
Study: 19074086
Drug: Adverse effects
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse effects of TPO receptor agonists
Study: 889511
Drug: 0.125% clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% clonidine hydrochloride solution
Study: 889511
Drug: 0.25% clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% clonidine hydrochloride solution
Study: 889511
Drug: 2% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% pilocarpine hydrochloride solution
Study: 25167875
Drug: 2 separate
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 separate injections (0.2 + 0.2 mL/kg) of contrast medium (gadoteridol) in Group A
Study: 25167875
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 0.4 mL/kg of contrast medium (gadoteridol) in Group B
Study: 16492643
Drug: Child receiving
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child receiving chemotherapy for cancer
Study: 12094850
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg once daily (group 15qd)
Study: 12094850
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg on alternate days (group 30qod)
Study: 12094850
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (15 mg daily and 30 mg alternate days)
Study: 10404055
Drug: Non-IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-IVIG treatment
Study: 7590046
Drug: Intravenous hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyoscine 20 mg plus inhaled oxygen on demand
Study: 7590046
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide on demand
Study: 7590046
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injection plus inhaled oxygen on demand (placebo)
Study: 2082315
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 10 mg
Study: 2082315
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 12.5 mg
Study: 2082315
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 100 mg
Study: 2082315
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 200 mg
Study: 2082315
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac 90 mg
Study: 2082315
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac 10 mg
Study: 2082315
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac 10 mg and 30 mg
Study: 2082315
Drug: Ketorolac doses
Normalized name: ketorolac Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac doses of 2.5 and 5 mg
Study: 2082315
Drug: Ketorolac doses
Normalized name: ketorolac Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac doses of 10 mg or more
Study: 2082315
Drug: Ketorolac doses
Normalized name: ketorolac Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac doses of 90 mg or more
Study: 476711
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin)
Study: 476711
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (cyclophosphamide and vincristine)
Study: 6851562
Drug: 21-day low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21-day low-dose combined pill
Study: 6851562
Drug: 21-day low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21-day low-dose combined pill followed by 7 days of iron-containing pill
Study: 6851562
Drug: 63-day low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 63-day low-dose combined pill followed by 7 days of no pill intake
Study: 19968839
Drug: Benznidazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (two doses)
Study: 12077585
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (methylprednisolone aceponate)
Study: 12077585
Drug: Systemic antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antifungal (terbinafine)
Study: 12077585
Drug: Systemic antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antifungal (itraconazole)
Study: 2668427
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g every 6 h)
Study: 327944
Drug: Intramuscular salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular salbutamol 20 microgram/kg
Study: 31769299
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (group cognitive rehabilitation programme delivered in 10 weekly sessions)
Study: 30561849
Drug: Prednisolone and
Normalized name: prednisolone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone and oral vitamin D (n=15)
Study: 28547999
Drug: Handwriting intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Handwriting intervention (self-managed at home, 1 hour, twice weekly for 6 months)
Study: 28399988
Drug: Y-SBNT (adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-SBNT (adapted youth social behaviour and network therapy)
Study: 24868255
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fat graft, laser CO2, and platelet-rich plasma (PRP)
Study: 18979616
Drug: Yoghurt containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt containing 1 g plant sterols (Study I)
Study: 18979616
Drug: Yoghurt containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt containing 2 g plant sterols (Study II)
Study: 16610925
Drug: Recycling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recycling intervention strategy to increase tobacco dependence treatment rates
Study: 12394419
Drug: Alprazolam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25, 0.50, 0.75 mg)
Study: 1487624
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg)
Study: 12394419
Drug: Buspirone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5, 10, 15 mg)
Study: 6499355
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 to 480 mg%)
Study: 6499355
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 to 360 mg%)
Study: 6499355
Drug: Verapamil (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (480 mg%)
Study: 29102613
Drug: Gluten (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (5.7 g)
Study: 29102613
Drug: Fructans (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructans (2.1 g)
Study: 10390389
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 micrograms twice daily (FP200)
Study: 10390389
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 micrograms twice daily (FP100)
Study: 8219927
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of acetaminophen
Study: 8219927
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acetaminophen)
Study: 3691593
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg daily